← Human Trials & Peer-Reviewed Studies
A comparison of misoprostol with and without methylergometrine and oxytocin in outpatient medical abortion: a phase III randomized controlled trial
Plain-language guide to PMID 37798748 (2023): randomized controlled trial study of Oxytocin in 90 patients.
Key Facts
- PMID
- 37798748
- Journal
- BMC research notes
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Jahromi AR et al. (4 authors)
- DOI
- 10.1186/s13104-023-06509-6
What This Study Did, in Plain Language
What Was Tested
Researchers studied Oxytocin in this randomized controlled trial publication.
The trial was registered in the Iranian registry of clinical trials on 04/10/2019.
( https://fa.irct.ir/trial/34519 ; registration number: IRCT20150407021653N19).
Who Took Part
The abstract describes 90 patients taking part.
The age groups tagged for this paper are infants, young adults and adults, women only.
In this randomized clinical trial, 90 patients participated with their gestational age below 12 weeks, each having undergone a recent miscarriage.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this Oxytocin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
After being screened for underlying diseases and coagulative blood disorders, they were randomly allocated into three groups.
For the first group, labeled as the control group, misoprostol was administered alone.
In contrast, the combination of misoprostol plus methylergometrine and misoprostol plus oxytocin was prescribed for the second and third groups, respectively.
Further, the data obtained were analyzed by descriptive and inferential statistics using Stata software version 14.
What Was Measured
Topics PubMed links to this paper include Misoprostol, Oxytocin, Methylergonovine, Oxytocics, Abortion, Spontaneous, Outpatients and Iran.
The authors tagged it with the keywords Ambulatory care, Clinical trial, First Trimester and Miscarriage.
What This Means in Plain Language
The paper is a randomized study of Oxytocin in 90 patients.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (BMC research notes), a journal based in England.
More context: the Oxytocin compound page, all human trials.
Our Notes on the Compound
Oxytocin: A peptide hormone with established obstetric medical uses and a less settled role in research on behavior, sexual function and appetite.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.